The Cooper Companies, Inc. (NASDAQ:COO) Given Consensus Recommendation of “Moderate Buy” by Analysts

The Cooper Companies, Inc. (NASDAQ:COO) has been given an average recommendation of “Moderate Buy” by the ten analysts that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $110.25.

A number of research analysts have issued reports on the company. Piper Sandler restated an “overweight” rating and issued a $115.00 price objective (down previously from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Citigroup lowered their price target on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a report on Friday, March 7th. BNP Paribas raised shares of Cooper Companies to a “hold” rating in a report on Thursday, March 13th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, March 7th.

Cooper Companies Stock Performance

Shares of COO stock opened at $83.77 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The firm has a 50-day moving average of $89.33 and a 200-day moving average of $97.29. Cooper Companies has a one year low of $77.05 and a one year high of $112.38. The company has a market cap of $16.75 billion, a P/E ratio of 42.96, a P/E/G ratio of 2.25 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. Equities research analysts forecast that Cooper Companies will post 3.98 EPS for the current fiscal year.

Institutional Trading of Cooper Companies

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Byrne Asset Management LLC purchased a new position in shares of Cooper Companies in the fourth quarter worth $33,000. OFI Invest Asset Management purchased a new position in Cooper Companies in the 4th quarter worth about $34,000. New Age Alpha Advisors LLC bought a new position in Cooper Companies during the 4th quarter valued at about $38,000. Covestor Ltd boosted its holdings in shares of Cooper Companies by 35.5% during the 4th quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock valued at $42,000 after acquiring an additional 120 shares during the last quarter. Finally, Brown Brothers Harriman & Co. grew its stake in shares of Cooper Companies by 191.0% in the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after acquiring an additional 275 shares during the period. 24.39% of the stock is currently owned by institutional investors.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.